No Data
Express News | Sailong pharmaceutical group: The application for supplementing 75mg specification of Pregabalin capsules has been approved.
Sailong Pharmaceutical Group (002898.SZ): Sailong Polyintelligence has cumulatively decreased its shareholding by 1%.
On November 4, Gelonhui, Sailong Pharmaceutical Group (002898.SZ) announced that it recently received a notice of equity change proportion reaching 1% from Zhuhai Hengqin New Area Sailong Juzhi Investment Co., Ltd., a shareholder holding over 5% of shares. It was informed that following the previous disclosure of the announcement on shareholders with more than 5% shareholding reducing shares by more than 1%, Sailong Juzhi reduced its shares by 130,000 shares through centralized auction trading from November 26, 2022, to November 28, 2022, and further reduced shares through centralized auction from May 4, 2023, to June 2, 2023.
Cailong Pharmaceuticals: Report for the third quarter of 2024
Sailong Pharmaceutical Group (002898.SZ): a net loss of 3.693 million yuan in the first three quarters.
On October 30, Gelonhui announced the third quarter report for 2024, with the company achieving revenue of 0.219 billion yuan in the first three quarters, a decrease of 2.94% year-on-year; net income attributable to shareholders of the listed company was -3.693 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -4.058 million yuan; basic earnings per share was -0.0210 yuan.
Sailong Pharmaceutical Gets Approval Notice for Fluorouracil Listing
The innovative drugs sector in the A-share market declined, with jiangsu aidea pharmaceutical falling more than 10%.
On September 13, Aidea Pharmaceutical dropped more than 10%, along with Sailong Pharmaceutical Group, Kain Technology, Brightgene Bio-Medical Technology Co.,Ltd., Hainan Poly Pharm, and Hongbo Pharmaceutical.
No Data
No Data